3PBIOVIAN Expands Isolator-Based Sterility Testing Across Clinical and Commercial Manufacturing Sites

Isolator-based sterility testing is fast becoming a differentiator in CDMO selection, and 3PBIOVIAN has moved to consolidate that position by expanding its sterility testing platform across both its Pamplona-Noáin and Turku facilities. The investment brings Drug Substance and Drug Product manufacturing into direct alignment with in-house analytical testing, removing the batch release delays that external laboratory dependencies typically introduce.

The operational logic is straightforward: isolator-based systems minimise operator intervention and environmental exposure, directly reducing the probability of contamination events, inconclusive results, and the costly repeat testing cycles that follow. For QA directors managing outsourced programmes, this translates to a more defensible sterility assurance posture and a cleaner audit trail when regulatory inspectors review release documentation.

3PBIOVIAN reports nearly three decades of sterility testing experience across protein-based and viral product types, a foundation that contextualises this capital investment as capability deepening rather than a greenfield build. The expanded platform supports seamless project progression from early clinical supply through commercial scale without handoffs to third-party laboratories, a structural advantage for sponsors managing 21 CFR Part 211 and EU GMP Annex 1 compliance obligations across a product's lifecycle.

For outsourcing partners currently benchmarking CDMO capabilities, the relevant checkpoint is whether integrated analytical testing is validated to the same standard as the manufacturing operations it supports. 3PBIOVIAN's dual-site model, covering microbial, mammalian, plasmid DNA, viral vector, and cell therapy product types, means the sterility testing expansion applies across a broad and complex product portfolio, not a single modality.

Batch release cycle time, a metric that directly affects clinical trial timelines and commercial supply commitments, will be the measurable outcome to track as the expanded platform moves into routine operation.

Source: 3PBIOVIAN via company press release, 7 May 2026.